- Business Wire•yesterdaySwedish Orphan Biovitrum AB: European Commission Grants SOBI003 Orphan Designation for the Treatment of MPS IIIA
Swedish Orphan Biovitrum AB has been granted orphan designation by the European Commission for the company’s development product candidate SOBI003, a chemically modified human recombinant sulfamidase for the treatment of mucopolysaccharidosis type IIIA .
- Business Wire•7 days ago
STOCKHOLM, Sweden-- -- On 27 October 2016, at 08:00 CET, Swedish Orphan Biovitrum AB will publish its report for the third quarter 2016. Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00 CET. The event will be hosted by Sobi’s CEO and President, Geoffrey McDonough, and the presentation will ...
Swedish Orphan Biovitrum AB (SOBI.ST)
Stockholm - Stockholm Delayed Price. Currency in SEK
|Day's Range||99.55 - 101.50|
|52wk Range||92.60 - 140.30|
|1y Target Est||N/A|
|P/E Ratio (ttm)||47.50|
|Avg Vol (3m)||851,395|
|Dividend & Yield||N/A (N/A)|